A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 58, Issue 1, Pages 153-161
Publisher
Informa UK Limited
Online
2016-04-28
DOI
10.1080/10428194.2016.1177772
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
- (2016) Valeria Magarotto et al. BLOOD
- Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
- (2015) M. Delforge et al. HAEMATOLOGICA
- Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
- (2015) M. Delforge et al. HAEMATOLOGICA
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
- (2014) M. Engelhardt et al. HAEMATOLOGICA
- Maintenance Therapy for Multiple Myeloma
- (2014) Philip L. McCarthy et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
- (2013) Fortunato Morabito et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
- (2013) Yandun Zou et al. LEUKEMIA & LYMPHOMA
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
- (2012) A. Palumbo et al. HAEMATOLOGICA
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
- (2012) Jesús F. San Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- “Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?”
- (2012) Philippe Moreau et al. LEUKEMIA RESEARCH
- Evidence Synthesis for Decision Making 2
- (2012) Sofia Dias et al. MEDICAL DECISION MAKING
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
- (2011) P. M. Fayers et al. BLOOD
- Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
- (2011) G. J. Morgan et al. BLOOD
- A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
- (2011) Stefano Sacchi et al. LEUKEMIA & LYMPHOMA
- Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review
- (2010) Ambuj Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
- (2010) A. Waage et al. BLOOD
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
- (2010) Meral Beksac et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
- (2010) Pierre Wijermans et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
- (2009) Cyrille Hulin et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started